| Thomas E Richtsmeier, MD | |
|
820 N Chelan Ave, Wenatchee, WA 98801-2028 | |
| (509) 663-8711 | |
| Not Available |
| Full Name | Thomas E Richtsmeier |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 820 N Chelan Ave, Wenatchee, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1942230354 | NPI | - | NPPES |
| 8510299 | Medicaid | WA | |
| 8947280 | Other | WA | CV |
| 0235549 | Other | WA | L&I |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | MD60004128 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Thomas E Richtsmeier, MD 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 | Thomas E Richtsmeier, MD 820 N Chelan Ave, Wenatchee, WA 98801-2028 Ph: (509) 663-8711 |
News Archive
AstraZeneca announced today it has received the 2010 EcoLeadership Award by the Alliance for Workplace Excellence for the second consecutive year. The EcoLeadership Award recognizes companies that demonstrate their commitment to environmental sustainability practices such as energy efficiency, waste minimization and water conservation.
To make sure that good ideas to enhance healthcare are not lost due to a lack of resources, a growing number of centers at Penn Medicine organize forums to pitch ideas to improve medical devices and technology, hold annual competitions to fund studies to improve patient care while keeping costs down, and sponsor seed grants for programs focused on patients who need individualized tailoring of their treatment.
By combining a magnetic nanoparticle, a fluorescent quantum dot, and an anticancer drug within a lipid-based nanoparticle, a multi-institutional research team headed by members of the National Cancer Institute's (NCI) Alliance for Nanotechnology in Cancer has created a single agent that can image and treat tumors. In addition, this new nanoparticle is able to avoid detection by the immune system, enabling the particle to remain in the body for extended periods of time.
About 70 percent of pharmaceuticals are manufactured using palladium-driven catalytic processes that are either fast or efficient - but not both.
› Verified 5 days ago
Dr. Ahmad Sabih Musmar, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Jonathan Andrew Bolles, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St Ste A, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Brett J. Hiendlmayr, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St, Wenatchee, WA 98801 Phone: 509-662-1511 | |
Kevin Joseph Struzzieri, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1201 S Miller St, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Dr. Brent A. Barber, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-663-8711 | |
Mircea Batanoiu, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 820 N Chelan Ave, Wenatchee, WA 98801 Phone: 509-663-8711 Fax: 509-665-6065 | |
Dr. Mark Douglas Johnson, M.D., MTM&H Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 933 Red Apple Rd, Wenatchee, WA 98801 Phone: 509-665-6210 Fax: 509-667-3310 |